Status
Conditions
Treatments
About
Total knee arthroplasty (TKA) is widely performed to reduce pain from advanced osteoarthritis, yet many patients experience severe postoperative pain and up to 25-44% develop chronic postsurgical pain (CPSP). Transcranial direct current stimulation (tDCS), a non-invasive neuromodulation technique, has shown promise in reducing pain and opioid use in early studies but has not been evaluated using comprehensive perioperative, home-based protocols. This study will test whether a home-based tDCS intervention delivered before and after TKA can improve acute pain management and reduce the development of CPSP.
Full description
Participants will self-administer 15 tDCS sessions using a home-based device during the perioperative period. Feasibility and acceptability will be assessed through device-recorded adherence data, participant diaries completed during the intervention period, and follow-up diary entries on postoperative days 14, 30, and 90. Findings will be used to refine the protocol and inform the design of a future large-scale trial evaluating the efficacy of home-based tDCS for postoperative pain management following TKA.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
History of brain surgery, central nervous system tumors, seizures (including epilepsy), stroke or intracranial implants (e.g plates, screws, deep brain stimulators)
Have vascular, traumatic, infectious, or metabolic lesions or diseases of the brain
Active diagnosis of a sleep disorder, defined as a documented diagnosis of any of the following conditions within the past 12 months, based on patient history or medical record review:
Active diagnosis of alcohol use disorder, defined as meeting DSM-5 criteria or documented in the patient's medical record within the past 12 months.
Patients taking opioid medications with a daily Oral Morphine Equivalent (OME) of ≥ 80 mg
Current use of medications or substances known to alter cortical excitability or possess psychoactive properties (e.g., antiepileptics, benzodiazepines, antidepressants, antipsychotics, hallucinogens, dissociatives), as determined by review of the patient's medication list, chart review, and patient history. This includes prescribed medications and illicit substances used within the past 30 days.
Have metallic implants or objects in or on the head, including mouth (e.g. electrodes, stents, clips, pins, braces, shrapnel, jewellery (unremovable)
Use passive or active implanted medical devices (e.g., pacemakers, defibrillators, cochlear implants, natural implants or active body-worn medical devices (e.g., neural stimulation or medication infusion devices)
Have defects in the neurocranium (e.g., post-skull trepanation)
Have large vessel occlusions (e.g., complete blockage of the internal carotid artery or other conditions affecting brain perfusion
Have skin diseases of the scalp
Are using other brain stimulation devices concurrently
Are pregnant
Are unable to provide informed consent
Are unable to wear or tolerate the study device
Unable to speak or read English, or understand device operation instructions
Primary purpose
Allocation
Interventional model
Masking
70 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Didem Bozak
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal